# Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

> **NCT02184585** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 84 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Treatment sequence A
- **DRUG:** Treatment sequence B
- **DRUG:** Treatment sequence C

## Key facts

- **NCT ID:** NCT02184585
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-10
- **Primary completion:** 2015-02-23
- **Final completion:** 2015-02-23
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184585, "Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02184585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*